Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorTianjin Medical University Cancer Institute and Hospital
About this trial
To explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.
Eligibility criteria
Qualifiers
Untreated locally advanced cervical cancer patients with clear pathological diagnosis
2019 FIGO stage IIIB-IVA. For patients with stage IIIC disease, the short diameter of their metastatic lymph nodes should ≥1.5cm
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Life expectancy > 6 months
Disqualifiers
Concomitant other malignancies;
Patients with metastatic or recurrent disease;
Patients received any form of treatment before enrollment;
Severe concomitant chronic diseases (diabetes, hypertension, etc.) or acute infections;
Trial design
Treatments tested in this trial
- Toripalimab
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1Tianjin Medical University Cancer Institute & Hospital300060, TianjinTianjin Municipality, China
Sponsors and collaborators
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor
Source ClinicalTrials.gov